Global Gynecological Cancers Market 2014-2018

TechNavio's analysts forecast the Global Gynecological Cancers market to grow at a CAGR of 12.47 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in prevalence of gynecological cancer. The Global Gynecological Cancers market has also been witnessing the emergence of personalized medicines. However, the increase in use of CAM could pose a challenge to the growth of this market.
TechNavio's report, the Global Gynecological Cancers Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Gynecological Cancers market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this space are Becton Dickinson and Co., Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., and GlaxoSmithKline plc.
Other vendor mentioned in the report is Merck & Co.
Key questions answered in this report:
What will the market size be in 2018 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Global Ovarian Cancers Market
06.3.1 Market Size and Forecast
06.4 Global Cervical Cancers Market
06.4.1 Market Size and Forecast
06.5 Global Uterine Cancer Market
06.5.1 Market Size and Forecast
06.6 Five Forces Analysis
07. Geographical Segmentation
08. Buying Criteria
09. Market Growth Drivers
10. Drivers and their Impact
11. Market Challenges
12. Impact of Drivers and Challenges
13. Market Trends
14. Trends and their Impact
15. Vendor Landscape
15.1 Competitive Scenario
15.1.1 Key News
15.1.2 Mergers and Acquisitions
15.2 Market Share Analysis 2013
15.3 Other Prominent Vendors
16. Key Vendor Analysis
16.1 Becton, Dickinson and Co.
16.1.1 Business Overview
16.1.2 Business Segmentation
16.1.3 Key Information
16.1.4 SWOT Analysis
16.2 Bristol Myers Squibb Co.
16.2.1 Business Overview
16.2.2 Key Information
16.2.3 SWOT Analysis
16.3 Eli Lilly and Co.
16.3.1 Business Overview
16.3.2 Key Information
16.3.3 SWOT Analysis
16.4 F. Hoffmann La Roche Ltd.
16.4.1 Business Overview
16.4.2 Business Segmentation
16.4.3 Key Information
16.4.4 SWOT Analysis
16.5 GlaxoSmithKline plc
16.5.1 Business Overview
16.5.2 Business Segmentation
16.5.3 Key Information
16.5.4 SWOT Analysis
17. Other Reports in this Series




List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Gynecological Cancers Market 2013-2018 (US$ billion)
Exhibit 3: Global Ovarian Cancers Market 2013-2018 (US$ billion)
Exhibit 4: Global Cervical Cancers Market 2013-2018 (US$ billion)
Exhibit 5: Global Uterine Cancer Market 2013-2018 (US$ billion)
Exhibit 6: Global Gynecological Cancers Market by Geographical Segmentation 2013
Exhibit 7: Business Segmentation of Becton, Dickinson and Co.
Exhibit 8: Business Segmentation of F. Hoffmann La Roche Ltd.
Exhibit 9: Business Segmentation of GlaxoSmithKline plc.